Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    29-October-2000      
Issue 199 Next Update - 14:00 UTC 08:00 EST    30-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Novel Study Compares Moxifloxacin And Azithromycin

Treatment Acute Exacerbations Of Chronic Bronchitis

The results of a novel "real world" study comparing the antibiotics moxifloxacin and azithromycin for treating acute exacerbations of chronic bronchitis (AECB) were presented today by Siegfried Kreis, MD, from Providence Healthcare Network, at the annual meeting of the American College of Chest Physicians and Clinical World Congress on Diseases of the Chest (CHEST). The multi-center study was unique in that it was based on patients treated by their usual physicians instead of by investigators in a research setting. The findings showed that, although the two antibiotics were equally effective in treating AECB, patients treated with moxifloxacin felt better faster.

"AECB is one of the most common respiratory tract infections and any treatment that helps patients feel better faster has implications for quality of life issues such as returning to work and patient well being" said Dr. Kreis, Chief of Infectious Disease and Chair of the Department of Internal Medicine at Providence Healthcare Network. "These findings suggest moxifloxacin may be a preferred choice of antibiotic for treating AECB," he said.

In the open-label study, 401 AECB patients from 74 physician practices were treated with moxifloxacin 400 mg daily for five days or azithromycin 500 mg the first day and 250 mg for the next four days. The primary outcome measure was the resolution of AECB symptoms (e.g., fever, coughing, shortness of breath) at 14-21 days ("test of cure"). Secondary outcomes were continued symptom resolution at 26-46 days after treatment ("follow-up") and patient assessments of the length of time, from the first antibiotic dose, required to perceive a clinical improvement and to return to normal activities.

Results showed moxifloxacin and azithromycin were equally effective at resolving symptoms: 85 percent and 81 percent of patients, respectively, at test of cure, and 81 percent and 79 percent, respectively, at follow-up. However, patients' subjective assessments showed those receiving moxifloxacin felt better sooner. For example, 40 percent of moxifloxacin patients reported clinical improvement after three days compared to 27 percent of azithromycin patients, a difference that was statistically significant (p < 0.012). Similarly, more moxifloxacin patients (36 percent) reported resuming normal activities after three days compared to azithromycin patients (26 percent), a difference which was nearly significant (p = 0.07). Adverse events were low for both regimens: 12 percent for moxifloxacin and 9 percent for azithromycin. The majority of adverse events were gastrointestinal, specifically nausea and diarrhea. Premature discontinuations due to adverse events were less than one percent for both groups.

The findings were part of the Therapeutic Circles program, sponsored by Bayer Corporation, which manufactures and markets moxifloxacin. An example of a new trend in medical research, Therapeutic Circles was initiated August 1999 to complement moxifloxacin pivotal trials, and was designed to evaluate the safety and effectiveness of the antibiotic in treating AECB patients seen in common clinical settings rather than the more controlled conditions of clinical trials. Unlike clinical trials, patients enrolled in the Therapeutic Circles trial through their own family doctor, enhancing patient familiarity and trust in their treatment. Physicians in the program were grouped into "Therapeutic Circles" in which they could discuss trial experiences with peers and gather qualitative information in addition to the usual quantitative information on safety and efficacy typically assessed in clinical trials.

Dr. Kreis said that conducting the study in everyday clinical settings makes the findings especially relevant to practicing physicians, and that assessing factors such as subjective patient assessments, not usually done in clinical trials, can provide valuable information. "The finding that patients felt better faster on moxifloxacin is important to practicing physicians -- and we wouldn't have known it without this type of study," he explained. He said the findings were so compelling that they should be verified in additional, larger studies.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.